Neuphoria Therapeutics Inc.
NEUP
$4.81
-$0.0271-0.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.10M | -10.71M | -15.38M | -18.06M | -20.58M |
| Total Depreciation and Amortization | 994.80K | 994.40K | 994.60K | 994.70K | 994.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5.85M | -3.95M | -990.10K | -1.63M | -2.30M |
| Change in Net Operating Assets | -72.00K | 43.90K | 1.76M | 3.32M | 4.89M |
| Cash from Operations | -13.03M | -13.62M | -13.62M | -15.37M | -16.99M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -141.00K | -141.00K | -141.00K | -133.30K | -127.70K |
| Cash from Investing | -141.00K | -141.00K | -141.00K | -133.30K | -127.70K |
| Total Debt Issued | -753.20K | -753.20K | -753.20K | -372.30K | -- |
| Total Debt Repaid | 55.90K | 55.90K | 55.90K | 53.90K | 52.80K |
| Issuance of Common Stock | 2.88M | 3.17M | 9.43M | 8.03M | 6.55M |
| Repurchase of Common Stock | -400.00 | -- | -- | -539.70K | -1.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.28M | 10.73M | 5.30M | 2.95M | 614.30K |
| Cash from Financing | 7.46M | 13.20M | 14.04M | 10.13M | 6.12M |
| Foreign Exchange rate Adjustments | 181.50K | 801.40K | 510.20K | 228.00K | -51.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.53M | 239.70K | 791.70K | -5.15M | -11.05M |
